Volume | 150,500 |
|
|||||
News | - | ||||||
Day High | 7.46 | Low High |
|||||
Day Low | 6.80 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Pulse Biosciences Inc | PLSE | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
6.91 | 6.80 | 7.46 | 7.45 | 6.95 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,121 | 150,500 | $ 7.11 | $ 1,070,627 | - | 3.78 - 13.62 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:04:19 | formt | 300 | $ 7.08 | USD |
Pulse Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
410.24M | 54.99M | - | 0 | -42.21M | -0.77 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Pulse Biosciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PLSE Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 8.05 | 8.23 | 6.6797 | 7.41 | 192,479 | -0.60 | -7.45% |
1 Month | 7.15 | 8.42 | 6.595 | 7.39 | 161,007 | 0.30 | 4.20% |
3 Months | 9.07 | 11.6398 | 6.595 | 8.49 | 168,905 | -1.62 | -17.86% |
6 Months | 4.62 | 13.62 | 4.571 | 9.17 | 234,495 | 2.83 | 61.26% |
1 Year | 8.40 | 13.62 | 3.78 | 7.84 | 198,516 | -0.95 | -11.31% |
3 Years | 17.16 | 29.16 | 1.18 | 7.16 | 154,598 | -9.71 | -56.59% |
5 Years | 12.50 | 45.82 | 1.18 | 9.71 | 128,561 | -5.05 | -40.40% |
Pulse Biosciences Description
Pulse Biosciences Inc is a medical therapy company that pursues the commercial introduction of its proprietary CellFX System utilizing its patent-protected Nano-Pulse Stimulation (NPS) platform technology. Through its proprietary CellFX System, the company can deliver a cell-focused effect on dysfunctional cells while preserving surrounding non-cellular tissue, a combination that may potentially lead to both improved efficacy and less collateral tissue damage. Substantial revenue is generated from North America Majorly due to the sale of systems. |